Unani formulation in Pelvic Inflammatory Disease

Efficacy of Unani formulation in Pelvic Inflammatory Disease-A randomised standard controlled clinical study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/018232

Enrollment

Registered

2019-03-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N74- Female pelvic inflammatory disorders in diseases classified elsewhere Health Condition 2: N74- Female pelvic inflammatory disorders in diseases classified elsewhere

Interventions

Intervention1: Khatmi(Althea officinalis Linn), Enabus saâ??lab(Solanum nigrum Linn),Maghze tukhme tarbooz(Citrullus vulgaris),Khaksi(Sisymbrium irio Linn),Benafsha(Viola odorata Linn) In Sharbat form

khaksi-4 gms chidak kar, orally 20ml two doses per day FOR 14 days Control Intervention1: Tab.Metrogyl 400mg Cap.Doxicyclin 100mg: Tab Metrogyl 400 mg thrice and Tab Doxicyclin100 mg twice daily for 1

Eligibility

Inclusion criteria

Inclusion criteria: Married women age group of 20-40 years Mild to moderate PID as per CDC Criteria (CDC diagnostic criteria i.e. pelvic or lower abdominal pain and uterine / adnexal or cervical motion tenderness and more than or equal to 1 of its minor criteria i.e. fever(101 degree F), abnormal cervical or vaginal mucopurulent discharge, abundant number of WBC on wet mount test of vaginal fluid, elevated ESR or CRP, positive test for cervical infection with N. gonorrhoea or C. trachomatis include in this criteria) Medical diagnosis of uncomplicated pelvic inflammatory disease(Sub-acute PID with mild to moderate signs and symtoms)

Exclusion criteria

Exclusion criteria: Severe PID and its Complications Pregnant and lactating women Systemic illnesses and malignancies A history of uterine or pelvic or abdominal surgery and less than 30days before treatment

Design outcomes

Primary

Measure	Time frame
change in subjective parameters.Timepoint: before and after treatment	—

Secondary

Measure	Time frame
change in objective parametersTimepoint: before and after treatment	—

Countries

India

Contacts

Public ContactDr Wajeeha Begum

National institute of Unani medicine

drwajeehanium@gmail.com9972550185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026